Australie - anglais - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium -

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

apotex nz ltd - montelukast sodium 10.4mg equivalent to montelukast 10 mg - tablet - 10 mg - active: montelukast sodium 10.4mg equivalent to montelukast 10 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - apo-montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day-time and night-time symptoms and the prevention of exercise-induced bronchospasm

Australie - anglais - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - montelukast sodium, quantity: 5.2 mg - tablet, chewable - excipient ingredients: croscarmellose sodium; aspartame; microcrystalline cellulose; iron oxide red; mannitol; magnesium stearate; flavour - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - montelukast sodium, quantity: 4.16 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; iron oxide red; magnesium stearate; mannitol; croscarmellose sodium; aspartame; flavour - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; macrogol 6000; iron oxide yellow; hypromellose; titanium dioxide; hyprolose; magnesium stearate; iron oxide red; lactose monohydrate; microcrystalline cellulose - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium -

Philippines - anglais - FDA (Food And Drug Administration)

hizon laboratories inc - montelukast (as sodium) - tablet, chewable - 5mg

Philippines - anglais - FDA (Food And Drug Administration)

pharex health corp - montelukast (as sodium) - tablet, chewable - 5mg

Philippines - anglais - FDA (Food And Drug Administration)

j.m. tolmann laboratories, inc. - montelukast (as sodium) - chewable tablet - 5mg

États-Unis - anglais - NLM (National Library of Medicine)

macleods pharmaceuticals limited - montelukast (unii: mhm278sd3e) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium chewable tablet is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium chewable tablet is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium chewable tablet is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. because the benefits of montelukast sodium chewable tablets may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium chewable tablet is not indicated for the treatment of an acute asthma attack. montelukast sodium chewable tablets is contraindicated in patients with hypersensitivity to any of its components. risk su